KRAS and squamous cell lung carcinoma: We found that patients with KRAS-variant squamous cell lung cancer had significantly worse OS than non-variant squamous patients (HR = 1.76, CI = 1.07–2.90, log-rank test P = 0.0307 stratified by as-treated radiation dose level and cetuximab).